Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end of the year. Tilray’s founder and CEO Brendan Kennedy highlights the company’s main differentiation factors, including but not limited to its international reach through its presence in ten countries on five different continents.
"We believe that a global paradigm shift around medical cannabis is upon us, and that the future winners of the industry will take the form of multinationals with trusted brands."
